MARINA KONOPLEVA to Morpholines
This is a "connection" page, showing publications MARINA KONOPLEVA has written about Morpholines.
Connection Strength
0.939
-
The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. Oncotarget. 2015 Nov 10; 6(35):37930-47.
Score: 0.459
-
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget. 2017 May 23; 8(21):34552-34564.
Score: 0.128
-
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
Score: 0.124
-
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells. Mol Cancer Ther. 2014 Jul; 13(7):1848-59.
Score: 0.103
-
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res. 2007 Jan 15; 67(2):684-94.
Score: 0.062
-
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol. 2014 Mar 01; 88(1):36-45.
Score: 0.025
-
Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma. Acta Haematol. 2014; 131(1):59-69.
Score: 0.025
-
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia. 2004 Feb; 18(2):267-75.
Score: 0.013